Compare PCT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | IRWD |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 556.5M | 578.3M |
| IPO Year | 2020 | 2009 |
| Metric | PCT | IRWD |
|---|---|---|
| Price | $1.72 | $4.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $6.40 | $6.18 |
| AVG Volume (30 Days) | ★ 8.6M | 2.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | $8,355,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $269.48 | $59.19 |
| Revenue Next Year | $262.99 | $4.80 |
| P/E Ratio | ★ N/A | $5.33 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.60 | $2.95 |
| 52 Week High | $14.20 | $5.78 |
| Indicator | PCT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 26.91 | 76.30 |
| Support Level | $1.60 | $3.90 |
| Resistance Level | $3.53 | N/A |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | -0.03 | 0.16 |
| Stochastic Oscillator | 6.20 | 93.10 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.